$2.43
4.29% today
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US14147L1089
Symbol
CRDF

Cardiff Oncology Inc Stock price

$2.43
-1.70 41.16% 1M
-1.91 44.01% 6M
-1.91 44.01% YTD
+0.17 7.52% 1Y
-0.61 20.07% 3Y
-3.09 55.94% 5Y
-443.97 99.46% 10Y
-969.57 99.75% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.10 4.29%
ISIN
US14147L1089
Symbol
CRDF
Industry

Key metrics

Basic
Market capitalization
$155.0m
Enterprise Value
$84.1m
Net debt
positive
Cash
$71.0m
Shares outstanding
66.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
281.8 | 368.7
EV/Sales
152.8 | 199.9
EV/FCF
negative
P/B
2.6
Financial Health
Equity Ratio
85.4%
Return on Equity
-54.8%
ROCE
-92.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$550.0k | $420.4k
EBITDA
$-54.0m | -
EBIT
$-54.3m | $-58.8m
Net Income
$-51.0m | $-54.0m
Free Cash Flow
$-41.9m
Growth (TTM | estimate)
Revenue
-16.7% | -38.2%
EBITDA
-22.0% | -
EBIT
-21.7% | -21.0%
Net Income
-24.9% | -18.7%
Free Cash Flow
-29.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-9,880.6% | -
EBIT
-9,950.9%
Net
-9,348.5% | -12,833.7%
Free Cash Flow
-7,668.7%
More
EPS
$-0.8
FCF per Share
$-0.6
Short interest
29.2%
Employees
33
Rev per Employee
$20.0k
Show more

Is Cardiff Oncology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Cardiff Oncology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Cardiff Oncology Inc forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Cardiff Oncology Inc forecast:

Buy
86%
Hold
14%

Financial data from Cardiff Oncology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.55 0.55
17% 17%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 13 13
12% 12%
2,449%
- Research and Development Expense 41 41
24% 24%
7,529%
-54 -54
22% 22%
-9,809%
- Depreciation and Amortization 0.38 0.38
10% 10%
69%
EBIT (Operating Income) EBIT -54 -54
22% 22%
-9,879%
Net Profit -51 -51
25% 25%
-9,280%

In millions USD.

Don't miss a Thing! We will send you all news about Cardiff Oncology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cardiff Oncology Inc Stock News

Neutral
The Motley Fool
13 days ago
Cardiff Oncology (CRDF) Q2 Loss Down 19%
Positive
Seeking Alpha
13 days ago
Onvansertib continues to show dose-dependent activity in KRAS-mutated mCRC, with response rates improving up to 49% in the high-dose arm. Recent data are less dramatic than early interim results, reflecting typical regression to the mean and leaving some questions unanswered until the next update in Q1 2026. CRDF's cash position is stable for now, but a future financing need is likely as the co...
Neutral
GlobeNewsWire
14 days ago
– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) –
More Cardiff Oncology Inc News

Company Profile

Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Head office United States
CEO Mark Erlander
Employees 33
Founded 1999
Website cardiffoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today